Background
The Fatty Liver Index (FLI) is a simple test that helps diagnose a liver condition linked to heart disease. This study looked at how two treatments, pemafibrate and omega-3 fatty acids, affect FLI in patients with cholesterol issues.
Methods
We included 117 participants: 57 took pemafibrate (0.4 mg daily) and 60 took omega-3 fatty acids (4 g daily). We measured changes in FLI and the prevalence of liver disease after 16 weeks.
Results
Both treatments lowered FLI significantly:
- Pemafibrate: FLI dropped from 69.7 to 47.6
- Omega-3: FLI dropped from 64.8 to 59.5
Pemafibrate showed a greater reduction in FLI compared to omega-3:
- Pemafibrate change: -18.3
- Omega-3 change: -5.5
At the start and after 16 weeks, the percentage of patients with liver disease was:
- Pemafibrate: 93.0% to 68.4%
- Omega-3: 90.0% to 85.0%
Conclusions
Pemafibrate is more effective than omega-3 fatty acids in reducing liver fat and the risk of liver disease in patients with high triglycerides. This suggests pemafibrate could be a valuable treatment option.
Practical Healthcare Solutions
Measurable Outcomes
Set clear goals for clinics and patients regarding the effectiveness of pemafibrate versus omega-3 fatty acids in improving liver health.
Select AI Tools
Choose AI solutions that meet specific clinical needs to analyze and enhance treatment strategies.
Implementation
Start with a pilot project to test the effectiveness of these treatments. Use AI tools to track the results and assess the real-world impact of the findings.
Contact Us
For AI solutions in medical management, reach out to us:
- Telegram: https://t.me/itinai
- X: https://x.com/vlruso
- LinkedIn: https://www.linkedin.com/company/itinai/
